Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Compass Therapeutics (CMPX – Research Report), Diamedica Therapeutics (DMAC – Research Report) and Veeva Systems (VEEV – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Compass Therapeutics (CMPX)
Canaccord Genuity analyst John Newman maintained a Buy rating on Compass Therapeutics today and set a price target of $13.00. The company’s shares closed last Thursday at $5.53.
According to TipRanks.com, Newman is a 2-star analyst with an average return of
Currently, the analyst consensus on Compass Therapeutics is a Strong Buy with an average price target of $13.40, a 135.5% upside from current levels. In a report issued on February 19, Craig-Hallum also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Diamedica Therapeutics (DMAC)
Lake Street analyst Thomas Flaten reiterated a Buy rating on Diamedica Therapeutics today and set a price target of $14.00. The company’s shares closed last Thursday at $7.74.
According to TipRanks.com, Flaten is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Diamedica Therapeutics with a $19.50 average price target.
Veeva Systems (VEEV)
BTIG analyst David Larsen maintained a Buy rating on Veeva Systems yesterday and set a price target of $340.00. The company’s shares closed last Thursday at $198.49.
According to TipRanks.com, Larsen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $270.05 average price target, a 43.3% upside from current levels. In a report issued on February 17, TipRanks – xAI also upgraded the stock to Buy with a $192.00 price target.
